CND Life Sciences
Develops an accurate, evidence-based tool that helps confirm a diagnosis of synucleinopathy.
Launch date
Employees
Market cap
-
Enterprise valuation
$25m (Public information from Mar 2024)
Phoenix Arizona (HQ)
Authorizing premium user...